Table 3.
Survival with selected adjuvant treatment in resected pancreatic cancer.
| CONKO-001 | ESPAC-1 | ESPAC-3v | ESPAC-4 | JASPAC-1 | PRODIGE 24 | APACT | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regimen | Gem | Obs | 5 FU + Folinic Acid | Obs | 5 FU + Folinic Acid | Gem | Gem + Cape | Gem | S1 | Gem | mFOLFIRINOX | Gem | PacliT + Gem | Gem |
| mOS (months) | 22.8 | 20.2 | 20.1 | 15.5 | 23.1 | 23.6 | 28 | 25.5 | 46.5 | 25.5 | 54.4 | 35 | 40.5 | 36.2 |
| HR (95% CI) | 0.76 | 0.66 | 0.94 | 0.82 | 0.57 | 0.64 | 0.82 | |||||||
| mDFS (months) | 13.4 | 6.7 | 14.1 | 14.3 | 13.9 | 13.1 | 22.9 | 11.3 | 21.6 | 12.8 | 19.4 | 18.8 | ||
| HR (95% CI) | 0.55 | 0.96 | 0.86 | 0.60 | 0.58 | 0.88 | ||||||||
| 5 yrs OS (%) | 20.7 | 10.4 | 21.1 | 8 | 15.9 | 17.5 | 28.8 | 16.3 | 44.1 | 24.4 | 63.4 (3 yrs OS) | 48.6 (3 yrs OS) | ||
Obs = observation; Gem = gemcitabine; 5 FU = 5-fluorouracil; Cape = capecitabine; mFOLFIRINOX = combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin.